drugset / Trial / NCT05611957

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

NCT05611957

Phase 1 Completed 29 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 5 weeks, excluding screening.

Timeline

Start
2022-11-16
Primary completion
2023-09-05
Completion
2023-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Retatrutide Protein / enzyme biologic Subcutaneous